Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of Perfusion Parameters on Outcomes and Safety of Endovascular Therapy in Posterior Cerebral Artery Stroke.

Stroke·2026
Same author

Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy.

Clinical nuclear medicine·2026
Same author

Endovascular thrombectomy for isolated posterior cerebral artery occlusion: distinct clinical presentation patterns and neurological outcomes in P1 versus P2 segments.

Frontiers in neurology·2026
Same author

Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.

Stroke·2026
Same author

Intra-Individual variation in radiation dose of pediatric head CT: implications for dose optimization.

Neuroradiology·2026
Same author

ESO annual stroke evidence update 2025.

European stroke journal·2026

Related Experiment Video

Updated: Jul 18, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Therapy for early reperfusion after stroke.

Eric Juttler1, Martin Kohrmann, Peter D Schellinger

  • 1Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. eric.juettler@med.uni-heidelberg.de

Nature Clinical Practice. Cardiovascular Medicine
|November 24, 2006
PubMed
Summary

Acute ischemic stroke treatment is limited, with few patients qualifying for current therapies. Research focuses on new reperfusion strategies to improve outcomes and extend the treatment window beyond 3 hours.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Induction of Ischemic Stroke and Ischemia-reperfusion in Mice Using the Middle Artery Occlusion Technique and Visualization of Infarct Area
09:08

Induction of Ischemic Stroke and Ischemia-reperfusion in Mice Using the Middle Artery Occlusion Technique and Visualization of Infarct Area

Published on: February 2, 2017

Related Experiment Videos

Last Updated: Jul 18, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Induction of Ischemic Stroke and Ischemia-reperfusion in Mice Using the Middle Artery Occlusion Technique and Visualization of Infarct Area
09:08

Induction of Ischemic Stroke and Ischemia-reperfusion in Mice Using the Middle Artery Occlusion Technique and Visualization of Infarct Area

Published on: February 2, 2017

Area of Science:

  • Neurology
  • Vascular Medicine
  • Pharmacology

Background:

  • Ischemic stroke is a major cause of death and disability.
  • Current standard treatment, intravenous tissue plasminogen activator, has a narrow 3-hour therapeutic window.
  • Limited patient eligibility for current treatments necessitates novel therapeutic approaches.

Purpose of the Study:

  • To review the current state of reperfusion therapy for acute stroke.
  • To integrate pharmacologic agents and delivery methods for stroke treatment.
  • To focus on plasminogen activator use in acute supratentorial infarction.

Main Methods:

  • Review of existing literature on stroke reperfusion therapies.
  • Analysis of pharmacologic agents and their delivery routes (intravenous and intra-arterial).
  • Discussion of plasminogen activators, antiplatelet agents, and anticoagulants.

Main Results:

  • Intravenous tissue plasminogen activator is the only approved therapy but has strict time limitations.
  • Research is actively exploring methods to achieve early reperfusion and extend the treatment window.
  • Alternative and adjunctive therapies like glycoprotein IIb/IIIa inhibitors are under investigation.

Conclusions:

  • There is a critical need for expanded treatment options for acute ischemic stroke.
  • Extending the therapeutic window beyond 3 hours is a key research objective.
  • Further research into novel reperfusion strategies is essential for improving patient outcomes.